<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">27771734</PMID>
<DateCompleted>
<Year>2017</Year>
<Month>05</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>06</Month>
<Day>06</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1643-3750</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>22</Volume>
<PubDate>
<Year>2016</Year>
<Month>Oct</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>Medical science monitor : international medical journal of experimental and clinical research</Title>
<ISOAbbreviation>Med. Sci. Monit.</ISOAbbreviation>
</Journal>
<ArticleTitle>Clinicopathological and Prognostic Factors in 106 Prostate Cancer Patients Aged ≤55 Years: A Single-Center Study in China.</ArticleTitle>
<Pagination>
<MedlinePgn>3935-3942</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>BACKGROUND Early-onset prostate cancer patients (aged ≤55 years) from Western countries have been well characterized in previous studies. However, the clinicopathological and prognostic characteristics of early-onset Chinese prostate cancer patients have not yet been assessed. This study aimed to examine the clinicopathological and prognostic factors of prostate cancer patients aged ≤55 years in a single Chinese center. MATERIAL AND METHODS One hundred six prostate cancer patients aged ≤55 years with complete clinicopathological data who were treated at our hospital between January 2000 and June 2014 were selected for this study. Survival rate was investigated by Kaplan-Meier analysis, and prognostic factors were examined by univariate and multivariate analysis. RESULTS The median time from the onset of symptoms to diagnosis was 3.5 months (range, 2-55 months). The median time after endocrine therapy to development of androgen-independent prostate cancer was 10.5 months. A total of 54 patients died (50.9%), of whom 96.2% died from prostate cancer. The 1-, 3-, and 5-year overall survival rates were 88.7%, 66.2%, and 36.0%, respectively. Univariate and multivariate analysis showed that T staging, visceral metastasis, pathological pattern, and Gleason sum were independent prognostic factors in these patients. CONCLUSIONS Prostate cancer patients aged ≤55 years are often omitted or misdiagnosed in China. Furthermore, the pathology patterns in this age group were mostly complicated with a high degree of malignancy. Late staging, visceral metastasis, pathological pattern, and high Gleason score were independent prognostic factors in these patients. Comprehensive therapy combined with local therapy is an effective treatment strategy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China (mainland).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Xueling</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China (mainland).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Si</LastName>
<ForeName>Tongguo</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China (mainland).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Haipeng</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China (mainland).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Weihao</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China (mainland).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Yong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China (mainland).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Zhi</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China (mainland).</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2016</Year>
<Month>10</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Med Sci Monit</MedlineTA>
<NlmUniqueID>9609063</NlmUniqueID>
<ISSNLinking>1234-1010</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 3.4.21.-</RegistryNumber>
<NameOfSubstance UI="D007610">Kallikreins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.-</RegistryNumber>
<NameOfSubstance UI="C549870">kallikrein-related peptidase 3, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.77</RegistryNumber>
<NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002681">China</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007610">Kallikreins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015999">Multivariate Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017430">Prostate-Specific Antigen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D064129">Prostatic Neoplasms, Castration-Resistant</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>Conflicts of Interest: None declared.</CoiStatement>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>10</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>5</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>10</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">27771734</ArticleId>
<ArticleId IdType="pii">901040</ArticleId>
<ArticleId IdType="pmc">PMC5081234</ArticleId>
<ArticleId IdType="doi">10.12659/msm.901040</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Urology. 2003 Dec 22;62(6 Suppl 1):3-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14706503</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Prostate. 2003 May 1;55(2):140-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12661039</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Urol. 2014 Jun;21(6):578-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24405474</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Clin Oncol. 1997 Dec;20(6):605-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9391550</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Urol. 2005 Sep;174(3):872-6; discussion 876</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16093978</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Epidemiol. 2015 Jul 29;7:355-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26251630</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2009 Jul 1;115(13):2863-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19466697</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2011 Sep 20;29(27):3695-704</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21859988</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2013 Aug 15;73(16):5163-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23946472</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Prostate Cancer Prostatic Dis. 2005;8(1):95-102</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15711606</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cancer. 2013;4(4):304-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23569463</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur Urol. 2012 Jun;61(6):1079-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22424666</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2003 Mar 8;361(9360):859-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12642065</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncology (Williston Park). 2014 Nov;28(11):974-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25403629</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Prostate. 2015 Jul 1;75(10 ):1034-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25753899</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Nutr. 2010 May;103(9):1375-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20082736</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BJU Int. 2014 Jul;114(1):38-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24053677</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Pathol. 2015 Jul;68(7):511-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25837493</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur Urol. 2014 Jun;65(6):1058-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24290503</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 2014 Dec 13;107(1):366</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25505238</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2013 Feb 11;23 (2):159-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23410972</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2012 May;23(5):1325-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21965474</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Prostate. 2014 Feb;74(3):321-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24259155</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2014 Dec 6;384(9959):2027-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25108889</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Urol. 2003 Nov;170(5):1828-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14532785</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Cancer. 2000 Jan 1;85(1):60-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10585584</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Cancer. 2006 Nov 15;119(10):2366-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16858675</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Cancer. 2011 Mar 15;128(6):1462-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20499312</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2012 Jun 15;118(12):3062-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22006014</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur Urol. 2012 Jan;61(1):8-9; discussion 9-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21889836</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>